BRAF and melanoma: This cohort included patients in which NGS testing revealed positivity for targets such as HER2/neu (ERBB2) in breast cancer specimens, androgen receptor (AR) in prostate cancer, BRAF in melanoma and EGFR mutation in NSCLC.